Table 1 Demographic and clinical characteristics of patients by period

Sex, male, n (%)

13 (50.0)

38 (45.2)

0.84

23 (47.9)

15 (41.7)

0.73

Age, months

16.5 (10, 29.5)

22 (16, 39.25)

0.03^b

24 (15, 47.5)

20.5 (16, 35)

0.45^b

History of febrile seizure, n (%)

3 (11.5)

21 (25.0)

0.18^a

11 (22.9)

10 (27.8)

0.80

Temperature on admission, °C

39.1 (38.4, 39.8)

38.65 (38.1, 39.4)

0.20

38.65 (38.1, 39.4)

38.65 (38.1, 39.4)

0.69

Convulsive seizure duration

150 (96.3, 345)

133.5 (88.5, 211.3)

0.30^b

125 (89.75, 210)

142.5 (84, 225.3)

0.81^b

Duration of hospital stay, days

9.5 (4.75, 19.8)

7.5 (5, 13)

0.17^b

7 (4, 12.3)

9 (5, 13)

0.21^b

Period from onset to determination of outcome, days

26 (20, 39.8)

32 (27, 38.3)

0.84

31 (17.8, 37.8)

35.5 (30, 38.3)

0.28

EEG monitoring, n (%)

3 (11.5)

72 (85.7)

<0.001^a

39 (81.3%)

33 (91.7%)

0.22^a

Intubation, n (%)

15 (57.7)

41 (48.8)

0.57

23 (47.9)

18 (50.0)

1

TTM, n (%)

11 (42.3)

38 (45.2)

0.97

20 (41.7)

18 (50.0)

0.59

Vasopressor, n (%)

13 (50.0)

37 (44.0)

0.76

20 (41.7)

17 (47.2)

0.78

Number of antiepileptic drugs used

3 (2, 3)

2 (2, 3)

0.43^b

2 (2, 3)

3 (2, 4)

0.07^b

Details of antiepileptic drugs used

 DZP, n (%)

25 (96.2)

74 (88.1)

0.45^a

44 (91.7)

30 (83.3)

0.31^a

 MDL, n (%)

19 (73.1)

69 (82.1)

0.47

38 (79.2)

31 (86.1)

0.59

 fPHT iv, n (%)

0 (0)

23 (27.4)

0.002^a

3 (6.3)

20 (55.6)

<0.001^a

 PB, n (%)

9 (34.6)

15 (17.9)

0.12

10 (20.8)

5 (13.9)

0.59

 MDL ci, n (%)

22 (84.6)

21 (25.0)

<0.001^a

19 (39.6)

2 (5.6)

<0.001^a

 Thiamylal ci, n (%)

9 (34.6)

38 (45.2)

0.47

20 (41.7)

18 (50.0)

0.59

 MDL+Thiamylal ci, n (%)

9 (34.6)

10 (11.9)

0.02

10 (20.8)

0 (0)

0.004^a

Time from onset to BCT initiation, h

5.5 (3.9, 37.1)

6.8 (5.0, 9.0)

0.97^b

6.3 (5.3, 9.0))

6.9 (4.9, 8.9)

0.87^b